Lieberthal et al., 1997 - Google Patents
O-Raffinose Crosslinking Substantially Ameliorates the Vasoconstrictive and Nitric-Oxide-Inactivating Effects of Unmodified Human Hemoglobin in the RatLieberthal et al., 1997
View PDF- Document ID
- 236654761594862629
- Author
- Lieberthal W
- Fuhro R
- Freedman J
- Toolan G
- Loscalzo J
- Publication year
External Links
Snippet
We studied the hemodynamic effects of a 20 exchange transfusion with whole blood or highly purified human hemoglobin Ao. We compared the effects of unmodified hemoglobin with o-raffinose crosslinked oligomers of hemoglobin modified hemoglobin. The unmodified …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4529719A (en) | Modified crosslinked stroma-free tetrameric hemoglobin | |
| JP3568541B2 (en) | Treatment of hemoglobin-containing erythrocytes with nitric oxide | |
| Lieberthal et al. | O-raffinose cross-linking markedly reduces systemic and renal vasoconstrictor effects of unmodified human hemoglobin | |
| CA2752943C (en) | A method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof | |
| Patel | Biochemical aspects of the reaction of hemoglobin and NO: implications for Hb-based blood substitutes | |
| Sehgal et al. | Large-volume preparation of pyridoxylated hemoglobin with high P50 | |
| Young et al. | Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys | |
| MX2008014648A (en) | Methods of treating acute blood loss anemia with a cross-linked hemoglobin blood substitute. | |
| Simoni et al. | ATP-adenosine-glutathione cross-linked hemoglobin as clinically useful oxygen carrier | |
| Sakai et al. | Fluid resuscitation with artificial oxygen carriers in hemorrhaged rats: profiles of hemoglobin-vesicle degradation and hematopoiesis for 14 days | |
| Levy | The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss | |
| Mozzarelli et al. | Chemistry and biochemistry of oxygen therapeutics: from transfusion to artificial blood | |
| Vandegriff | Blood substitutes: engineering the haemoglobin molecule | |
| Scatena et al. | O-raffinose-polymerised haemoglobin. A biochemical and pharmacological profile of an oxygen carrier | |
| Lieberthal et al. | O-Raffinose Crosslinking Substantially Ameliorates the Vasoconstrictive and Nitric-Oxide-Inactivating Effects of Unmodified Human Hemoglobin in the Rat | |
| Hess | Blood substitutes for surgery and trauma: efficacy and toxicity issues | |
| Juel et al. | 2, 3-Diphosphoglycerate: its role in health and disease | |
| Marchand et al. | Resuscitation with increasing doses of diaspirin crosslinked hemoglobin in swine | |
| Friedman et al. | Hemoglobin solutions as blood substitutes | |
| MESSMER | Oxygen-carrying blood substitutes | |
| Woodson et al. | Effect of osmotic shrinking and swelling of red cells on whole blood oxygen affinity | |
| Rudolph | * HemAssist™: Development and Clinical Profile | |
| Holowaychuk et al. | Hemoglobin‐Based Oxygen Carrier Solutions | |
| Nelson | Clinical Profile | |
| WO2024112490A2 (en) | Nitrosyl-heme formulations for the treatment cardiovascular conditions, hemolysis, and the stabilization of cell-free heme molecules |